Company / Working Capital
Apellis Pharmaceuticals, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$691.2M
FY2025
5-year range
$518.7M / $692.2M
FY2021-FY2025
Trend
+14.5%
vs FY2024
Sector context
#63 of 213
Health Care
What the data says
At $691M, Apellis Pharmaceuticals, Inc.'s working capital ranks #63 of 213 in the Health Care sector. Improved from $519M to $691M over the past 2 years.
Based on SEC 10-K filings.
$691M in FY2025 with a 5-year CAGR of -2.6%.
Improved from $519M to $691M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +7.8%
- 5-Year CAGR
- -2.6%
- 10-Year CAGR
- -
Sector benchmark
#63 of 213 in Health CareTop 30% of 213This company $691.2M Sector average $934.6M
▼
-26.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.6%, indicating a declining trend.
- In FY2025, working capital increased 14.5% year-over-year.
- Ranks #63 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $691.2M | +14.5% |
| FY2024 | $603.4M | +16.3% |
| FY2023 | $518.7M | -6.0% |
| FY2022 | $551.9M | -20.3% |
| FY2021 | $692.2M | -12.3% |
| FY2020 | $788.9M | +156.7% |
| FY2019 | $307.3M | +65.8% |
| FY2018 | $185.4M | +5.7% |
| FY2017 | $175.5M | +639.4% |
| FY2016 | $23.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026